EKF Diagnostics Holdings plc
("EKF", the "Company" or the "Group")
Change of Adviser
EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed point-of-care business, announces the appointment of Investec Bank plc as joint corporate broker, with immediate effect to work alongside its existing nominated adviser and broker, N+1 Singer.
Julian Baines, CEO of EKF, commented:
"We outlined at our AGM last month a strategy to deliver significant earnings growth over the next 3 to 4 years and we are delighted to have the support of both N+1 Singer and Investec as our joint brokers as we enter into this next phase of accelerated growth."
|
EKF Diagnostics Holdings plc |
||
|
Christopher Mills, Non-executive Chairman |
Tel: +44 (0)29 2071 0570 |
|
|
Julian Baines, CEO |
|
|
|
Richard Evans, FD & COO |
|
|
|
|
|
|
|
N+1 Singer (Nominated Adviser & Joint Broker) |
Tel: +44 (0)20 7496 3000 |
|
|
Aubrey Powell / George Tzimas / Tom Salvesen |
|
|
|
|
|
|
|
Investec Bank plc (Joint Broker) |
Tel: +44 (0)20 7597 4000 |
|
|
Gary Clarence / Daniel Adams |
|
|
|
|
|
|
|
Walbrook PR Limited |
Tel: +44 (0)20 7933 8780 or ekf@walbrookpr.com |
|
|
Paul McManus / Lianne Cawthorne |
Mob: +44 (0)7980 541 893 / +44 (0)7584 391 303 |
|
About EKF Diagnostics Holdings plc (www.ekfdiagnostics.com)
EKF is a leading point-of-care diagnostics and central laboratory assay manufacturer with an estimated 80,000 hemoglobin, hematocrit, HbA1c, glucose and lactate analysers in regular use across more than 100 countries. EKF specialises in developing tests for use in anemia and diabetes diagnosis and management, as well as providing a portfolio of reagents for use in clinical chemistry analysers.
EKF specialises in the development, production and worldwide distribution of point-of-care analyzers and clinical chemistry reagents for use in hospital and research laboratories, doctor's offices, blood banks and for in-field anaemia screening programmes. EKF is also a bulk manufacturer of enzymes and has custom manufacturing facilities in the across sites in the US, UK and Europe for a variety of life science products. Demand for contract manufacturing of COVID-19 sample collection tests and kits has grown dramatically during the pandemic, however the capabilities can be applied to other areas of diagnostic testing, molecular disease and forensic test manufacture.